S. Kang

发表

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2013, The New England journal of medicine.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J. Lunceford, J. Wolchok, H. Zarour, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Wei Zhou, Dirk Schadendorf, Reinhard Dummer, 2015, The Lancet. Oncology.

J. Lunceford, T. Mcclanahan, M. Ayers, 2017, The Journal of clinical investigation.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Ludmila V. Danilova, L. Cope, A. Zaheer, 2017, Science.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2014, The Lancet.

J. Lunceford, T. Mcclanahan, M. Ayers, 2019 .

Pembrolizumab

M. Butler, S. Ebbinghaus, S. Kang, 2018, Reactions Weekly.

Pembrolizumab

M. Butler, S. Ebbinghaus, S. Kang, 2015, Journal of Immunotherapy for Cancer.

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Sung-Bae Kim, M. Shah, F. Lordick, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study

Sung-Bae Kim, J. Lunceford, M. Shah, 2019, JAMA oncology.

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Lon Smith, Omar Laterza, Robert H Pierce, 2015, Clinical Cancer Research.

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors

M. Ratain, J. Tabernero, C. Kahatt, 2014, Clinical Cancer Research.

A Blueprint to Advance Colorectal Cancer Immunotherapies

Vanessa M. Hubbard-Lucey, L. Diaz, E. Jaffee, 2017, Cancer Immunology Research.

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

Y. Bang, C. Fuchs, E. Van Cutsem, 2020, JAMA oncology.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

J. Wolchok, A. Ribas, F. Hodi, 2018, Clinical Cancer Research.

Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.

Tae Won Kim, L. Diaz, E. Van Cutsem, 2017 .

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

J. Wolchok, H. Zarour, A. Ribas, 2016, JAMA.

KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).

D. Jäger, L. Diaz, J. Bendell, 2018 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

A. Hauschild, D. Schadendorf, R. Dummer, 2016, European journal of cancer.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

J. Wolchok, A. Ribas, F. Hodi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

D. D. de Alwis, E. Rubin, G. Lubiniecki, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)

J. Wolchok, A. Ribas, F. Hodi, 2018 .

Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells

P. Friedman, L. Harris, F. You, 2008, Journal of hematology & oncology.

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Thomas O Jemielita, James R. Anderson, Meihua Wang, 2019, Journal of Immunotherapy for Cancer.

KEYNOTE-177: Randomized phase III study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma.

D. Jäger, L. Diaz, J. Bendell, 2017 .

Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial

S. Kang, J. Elassaiss-Schaap, S. P. Kang, 2016, CPT: pharmacometrics & systems pharmacology.